1. AB0395 Subcutaneous tocilizumab as monotherapy or in combination with a csdmard in patients with rheumatoid arthritis: 24 weeks results of the french phase iiib study, "tosca". (15th June 2017) Authors: Fautrel, B; Senbel, E; Vittecoq, O; Rist, S; Combe, B; Schaeverbeke, T; Lioté, F; Flipo, R-M; Baffie, C; Pau, D; Fraga, E Condé Da Silva; Pinta, A; Gaudin, P Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0701 The real-life use of golimumab in patients with immune-mediated rheumatic diseases: one year results of the go-practice study. (15th June 2017) Authors: Flipo, R-M; Tubach, F; Ouaniche, J; Goupille, P; Lespesailles, E; Gouyette, N; Bertin, P; Fautrel, B Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1299 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Issue 10 (28th October 2008) Authors: Terrier, B; Saadoun, D; Sène, D; Ghillani, P; Amoura, Z; Deray, G; Fautrel, B; Piette, J-C; Cacoub, P Journal: Annals of the rheumatic diseases Issue: Volume 68:Issue 10(2009) Page Start: 1564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Bone marrow oedema predicts structural progression in a 1-year follow-up of 85 patients with RA in remission or with low disease activity with low-field MRI. Issue 12 (22nd August 2011) Authors: Gandjbakhch, F; Foltz, V; Mallet, A; Bourgeois, P; Fautrel, B Journal: Annals of the rheumatic diseases Issue: Volume 70:Issue 12(2011) Page Start: 2159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Issue 1 (30th June 2005) Authors: Le Loët, X; Berthelot, J M; Cantagrel, A; Combe, B; De Bandt, M; Fautrel, B; Flipo, R M; Lioté, F; Maillefert, J F; Meyer, O; Saraux, A; Wendling, D; Guillemin, F Journal: Annals of the rheumatic diseases Issue: Volume 65:Issue 1(2006) Page Start: 45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. Issue 1 (5th May 2020) Authors: Fautrel, B; Zhu, B; Taylor, P C; van de Laar, M; Emery, P; De Leonardis, F; Kannowski, C L; Nicolay, C; Kadziola, Z; De La Torre, I; Fleischmann, R Journal: RMD open Issue: Volume 6:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial. Issue 2 (9th September 2009) Authors: Fautrel, B; Benhamou, M; Breban, M; Roy, C; Lenoir, C; Trape, G; Baleydier, A; Ravaud, P; Dougados, M Journal: Annals of the rheumatic diseases Issue: Volume 69:Issue 2(2010) Page Start: 424 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Issue 4 (17th January 2011) Authors: Soubrier, M; Lukas, C; Sibilia, J; Fautrel, B; Roux, F; Gossec, L; Patternotte, S; Dougados, M Journal: Annals of the rheumatic diseases Issue: Volume 70:Issue 4(2011) Page Start: 611 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Issue 4 (21st December 2010) Authors: Salmon-Ceron, D; Tubach, F; Lortholary, O; Chosidow, O; Bretagne, S; Nicolas, N; Cuillerier, E; Fautrel, B; Michelet, C; Morel, J; Puéchal, X; Wendling, D; Lemann, M; Ravaud, P; Mariette, X Journal: Annals of the rheumatic diseases Issue: Volume 70:Issue 4(2011) Page Start: 616 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. Issue 1 (17th May 2016) Authors: Hifinger, M; Hiligsmann, M; Ramiro, S; Watson, V; Severens, J L; Fautrel, B; Uhlig, T; van Vollenhoven, R; Jacques, P; Detert, J; Canas da Silva, J; Scirè, C A; Berghea, F; Carmona, L; Péntek, M; Keat, A; Boonen, A Journal: Annals of the rheumatic diseases Issue: Volume 76:Issue 1(2017) Page Start: 126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗